The latest announcement is out from Acumen Pharmaceuticals (ABOS).
The Company has announced an update to its corporate presentation, indicating a strategic change in its ALTITUDE-AD Phase 2/3 study, which will now be revised to a Phase 2 standalone study. This information is intended for informational purposes and is not legally filed under the Securities Exchange Act of 1934, nor is it subjected to its associated liabilities. It also does not form part of any official filing unless explicitly stated in such a document.
For detailed information about ABOS stock, go to TipRanks’ Stock Analysis page.
